AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...

Greater proportion of upadacitinib-treated patients attained near-complete skin clearance in the head and neck region.

Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...

AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...

AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing ...

For once, the EMA appears to have pipped the U.S. FDA to the post, with Pfizer Inc.’s hemophilia A and B therapy Hympavzi (marstacimab) recommended for approval in Europe on Sept. 20, while the U.S.

AbbVie (NYSE: ABBV) shares lost ground Friday. The company announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion ...